Long-Term Open-Label Extension Study of Oral Levosimendan
A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 800 participants.
Also called NCT07436689
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 800 participants
- Sponsor
- Registry
-
NCT07436689
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT07436689. Allocation not applicable; no masking; primary purpose treatment. Start 2026-03-13 (actual); primary completion 2029-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-Term Open-Label Extension Study of Oral Levosimendan
- Condition
- Pulmonary Hypertension Associated With HFpEF
- Intervention (Drug)
- TNX-103
- Lead sponsor
- Tenax Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct07436689- Content hash
f36d37cb5bd4290b0f540457c1d622f89ae70de47d7e51a6633a871e80677b5c